Jade Biosciences (JBIO) Receivables - Accured (2021 - 2022)

Jade Biosciences (JBIO) reported Receivables - Accured of $100000.0 for Q1 2022, little changed quarter-over-quarter from $100000.0 in Q4 2021.

Jade Biosciences (JBIO) Receivables - Accured (2021 - 2022) Analysis & Trends

Jade Biosciences has reported Receivables - Accured for 2 years, with the latest figure at $100000.0 in Q1 2022.

For the quarter ending Q1 2022, Receivables - Accured changed N/A year-over-year to $100000.0; the trailing twelve-month figure through Mar 2022 stood at $100000.0 (changed N/A YoY), and the FY2021 full-year result was $100000.0, changed N/A from the prior year.
Receivables - Accured for Q1 2022 stood at $100000.0, roughly flat from $100000.0 in the prior quarter.
The five-year high for Receivables - Accured was $100000.0 in Q2 2021, with the low at $100000.0 in Q2 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Acc. Int. Receivables (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	-
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	-
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Jade Biosciences	973.55 Mn	973.55 Mn	-	-

Download Data